Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 235

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 235
---
The Company, therefore,
anticipates that substantial additional funding will be needed in connection with its continuing operations. At September 30, 2024, the
Company had $3.4 million and at January 7, 2025, the Company had approximately $5.539 million in cash, restricted cash and cash
equivalents. The Company intends to devote most of the available cash to the preclinical and clinical development of its product candidates
and public company compliance costs. Based on current business plans, the Company believes that the cash available at September 30, 2024
will not fund its operations and capital requirements for 12 months after the filing of the unaudited financial statements for the nine-month
period ended September 30, 2024. The Company has arranged two equity lines of credit, one providing for the sale of up to 25,000,000
newly issued shares of Common Stock and the other providing for the purchase of up to $25 million of Common Stock on the satisfaction
of certain conditions. At September 30, 2024, the Company had 2.8 million shares remaining in the first ELOC, which was fully depleted
on October 3, 2024, and $25 million remaining in the second ELOC, which was replaced with a second ELOC arranged with the investor in
the first ELOC (see Note 12 – Subsequent Events). The Company has no guarantee that the conditions will be satisfied to require
the purchase of all, or any additional amount, of the Equity Line of Credit (“ELOC”) funds. Any estimate as to how long the
Company expects the net proceeds from the ELOC funding may fund the Company’s operations is based on assumptions that may prove
to be wrong, and the Company could use its available capital resources sooner than its current expectations. Changing circumstances,
some of which may be beyond the Company’s control, could result in less cash and cash equivalents available to fund operations
or cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to seek additional
funds from additional sources sooner than planned.

Because of the numerous
risks and uncertainties associated with research, development and commercialization of pharmaceutical drug products, the Company is unable
to estimate the exact amount of its operating capital requirements. The Company’s future funding requirements will depend on many
factors, including, but not limited to those listed under “Factors Affecting Our Performance” above.

<div align='center